| Literature DB >> 30606216 |
Huan Li1, Wei Peng1, Shu Huang2, Yutang Ren3, Yan Peng1, Qing Li1, Jiao Wu1, Xiangsheng Fu4, Xiaowei Tang5.
Abstract
AIM: In this retrospective review, we aimed to investigate the long-term efficacy and safety of POEM with follow-up period over 2 years.Entities:
Keywords: Achalasia; Clinical success; Complications; Efficacy; Peroral endoscopic myotomy; Systematic review
Mesh:
Year: 2019 PMID: 30606216 PMCID: PMC6318943 DOI: 10.1186/s13019-018-0811-9
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Fig. 1PRISMA flowchart for search strategy of this systematic review
The characteristics of patients associated with this study
| Author | Country | Study design | Year | Case | M/F | Mean age (range) (years) | Mean symptoms duration (range) (months) | Prior treatment n(%) | Mean follow-up (range) (months) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBD | BTI | LHM | Others | Overall | |||||||||
| Hu et al. [ | China | Prospective | 2015 | 32 | 17/15 | 43.6 (18.0~72.0) | 40.8 (1.2~600.0) | 14 (43.8) | 3 (9.4) | 3 (9.4) | 3 (9.4) | 23 (71.9) | 30.0 (24.0~44.0) |
| Peng et al. [ | China | Retrospective | 2017 | 13 | 8/5 | 37.5 ± 13.0 | 46.8 ± 33.6 | 3 (23.1) | 0 (0) | 0 (0) | 3 (23.1) | 6 (46.2) | 46.2 ± 4.1 |
| Zhang et al. [ | China | Retrospective | 2017 | 32 | 16/16 | 43.3 (16.0~79.0) | 24.0 (2.4~336.0) | 0 (0) | 1 (3.1) | 0 (0) | 0 (0) | 1 (3.1) | 27.0 (24.0~51.0) |
| Chen et al. [ | China | Prospective | 2015 | 27 | 11/16 | 13.8 (6.0~17.0) | 20.4 (2.4~36.0) | 5 (18.5) | 1 (3.7) | 0 (0) | 9 (33.3) | 15 (55.6) | 24.6 (15.0~38.0) |
| Lv et al. [ | China | Retrospective | 2016 | 6 | 1/5 | 49.0 (21.0~72.0) | 96.0 (24.0~300.0) | 0 (0) | 0 (0) | 0 (0) | 2 (33.3) | 2 (33.3) | 34.5 (median) |
| Zhang et al. [ | China | Retrospective | 2017 | 21 | 9/12 | 38.0 (15.0~64.0) | 26.0 (10.0~360.0) | 0 (0) | 3 (14.3) | 0 (0) | 1 (4.8) | 4 (19.1) | 42.0 (9.0~62.0) |
| Meng et al. [ | China | Retrospective | 2017 | 32 | 13/19 | 44.8 ± 11.6 | 24.0 (12.0~60.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 25.0 ± 11.0 |
| Duan et al. [ | China | Retrospective | 2017 | 123 | 63/60 | 42.1 (14.0~74.0) | 60.0 (6.0~396.0) | 11 | 4 | 0 (0) | 3 | 18 | 30.0 (24.0~46.0) |
| Teitelbaum et al. [ | USA | Prospective | 2017 | 36 | 16/20 | 55.0 (20.0~88.0) | NR | NR | NR | 0 (0) | 18 (50.0) | 18 (50.0) | 65.0 (median) |
| Amy Tyberg et al. [ | USA | Prospective | 2017 | 51 | 24/27 | 54.2 | 134.4 | 0 (0) | 0 (0) | 43 (84.0) | NR | 45 (88.0) | 24.4 (12.0~52.0) |
| Total | 373 | 178/195 | 42.1 | 52.5 | 33 (8.8) | 12 (3.2) | 46 (12.3) | 39 (10.5) | 132 (35.4) | 30.0 | |||
NR Not reported, M/F Male/Female, EBD Endoscopic balloon dilatation, BTI:Botulinum toxin injections, LHM:Laparoscopic Heller myotomy
The treatment characteristics of the peroral endoscopic myotomy(POEM)
| Author | Mean submucosal tunnel length (cm) | Mean Myotomy length (cm) | Mean Operative Time(range)(min) | Mean hospital stay (days) | Complications n(%) | Replacement therapy n(%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Esoph-ageal | Gastric | Overall | Subcutaneous emphysema | Pneumo-thorax | Mucosa perforation | Mediastinal emphysema | Pneumope-ritoneum | Others | Overall | |||||
| Hu et al. [ | NR | 8.0 (5~11) | 2.3 (2~5) | 10.3 (7~14) | 63.7 (22~130) | 3.9 (1.0~29) | 4 (14.3) | 1 (3.6) | 12 (37.5) | 10 (35.7) | 7 (25.0) | NR | 28 (87.5) | 0 (0) |
| Peng et al. [ | 11.0 | NR | NR | 7.5 ± 1.3 | 93.4 ± 23.5 | 4.0 (3.5~4.5) | 0 (0) | 1 (7.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (7.7) | 0 (0) |
| Zhang et al. [ | 9.3 (4.0~14.0) | NR | NR | 8.2 (3.0~15.0) | 34.9 (17.9~88.6) | NR | 0 (0) | 1 (3.1) | 0 (0) | 0 (0) | 4 (12.5) | 1 (3.1) | 6 (18.8) | 0 (0) |
| Chen et al. [ | NR | 7.4 (5~9) | 2.2 (2~4) | 9.6 ± 1.1 (7~11) | 39.4 ± 17.4 (21.0~90.0) | 3.2 ± 1.2 (1.0~7.0) | 7 (36.8) | 3 (15.8) | 5 (19.2) | 10 (52.6) | 9 (47.4) | NR | 9 (34.6) | 1 (3.7) |
| Lv et al. [ | 12.0 (median) | NR | NR | 10.0 (median) | 76.7 ± 22.3 | 6.0 (median) | 0 (0) | 0 (0) | 1 (16.7) | NR | NR | NR | 6 (100) | 0 (0) |
| Zhang et al. [ | 11.7 (7.0~18.0) | NR | NR | 5.6 (3.0~10.0) | 58.9 (20.0~141.0) | 5.0 (5.0~7.0) | 0 (0) | 1 (4.8) | 0 (0) | 1 (4.8) | 1 (4.8) | 0 (0) | 3 (14.3) | 0 (0) |
| Meng et al. [ | 13.0 (12.0~14.0) | NR | NR | 8.0 (7.0~8.0) | 72.5 (40.0~180.0) | 8.0 (6.0~10.0) | 4 (12.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (12.5) | 0 (0) |
| Duan et al. [ | 13.6 ± 1.2 | NR | NR | 10.5 ± 1.3 | 60.3 ± 10.3 | 5.5 | NR | NR | 3 (2.4) | NR | NR | 11 (8.9) | 14 (11.4) | 0 (0) |
| Teitelbaum et al. [ | NR | NR | NR | NR | 130.0 (60.0~220.0) | 1.0 (1.0~2.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2.8) | 1 (2.8) | 0 (0) |
| Amy Tyberg et al. [ | NR | NR | NR | 13.5 (12~15) | NR | NR | 0 (0) | 0 (0) | 6 (NR) | 0 (0) | 0 (0) | 2 (NR) | 7 (13.0) | 0 (0) |
| Total | 11.72 | 7.7 | 2.3 | 9.3 | 66.7 | 4.2 | 15 (18.99) | 7 (8.86) | 27 (34.2) | 21 (26.6) | 21 (26.6) | 15 (18.99) | 79 (21.2) | 1 (0.3) |
The postoperative outcomes
| Author | Mean LESP (mmHg) | Mean Eckardt score | GER /RE n(%) | Clinical success n(%) | ||
|---|---|---|---|---|---|---|
| Preoperative | Postoperative | Preoperative | Postoperative | |||
| Hu et al. [ | 37.9 (21.9~70.3) | 12.9 (7.7~22.5) | 7.8 (4.0~12.0) | 1.4 (0~5.0) | 8 (25.8) | 30 (96.8) |
| Peng et al. [ | NR | NR | 7.5 ± 1.3 | 2.6 ± 1.5 | 1 (8.3) | 9 (83.3) |
| Zhang et al. [ | 39.2 (19.4~78.0) | 19.0 (10.8~30.6) | 7.2 (4.0~11.0) | 1.4 (0~5.0) | 6 (18.8) | 29 (90.6) |
| Chen et al. [ | 31.6 ± 9.1 (16.0~45.3) | 12.9 ± 4.3 (6.1~21.0) | 8.3 ± 1.6 (6.0~12.0) | 0.7 ± 0.8 (0~2.0) | 5 (19.2) | 26 (100) |
| Lv et al. [ | 35.3 ± 4.4 | 12.8 ± 2.7 | 7.0 (median) | 1.5 (median) | 1 (16.7) | NR |
| Zhang et al. [ | 31.9 (21.9~67.1) | 20.3 (6.0~41.0) | 5.0 (4.0~10.0) | 1.0 (0~4.0) | 3 (14.3) | 20 (95.2) |
| Meng et al. [ | 28.0 ± 10.9 | 12.6 ± 6.5 | 6.94 ± 2.14 | 1.1 ± 1.0 | 6 (18.8) | NR (94.8) |
| Duan et al. [ | 34.5 ± 7.06 | 11.8 ± 5.1 | 7.3 ± 1.8 | 0.56 ± 0.78 | 6 (4.9) | 121 (98.4) |
| Teitelbaum et al. [ | 23.0 ± 15.0 | NR | 6.2 ± 2.6 | 1.7 ± 1.6 | 2 (13.0) | 19 (83.0) |
| Amy Tyberg et al. [ | NR | NR | 7.98 ± 2.11 | 1.72 ± 1.5 | 0 (0) | 48 (94.0) |
| Total | 32.8 | 13.7 | 7.4 | 1.4 | 38 (10.2) | 302 (92.9) |
LESP Lower esophageal sphincter pressure, Eckardt’s Eckardt score, GER /RE Gastroesophageal reflux/ Reflux esophagitis
Clinical success: Eckardt score≤3